acomplia diet drug - Smoking cessation Despite the FDA issuing an approvable letter in February 2006 for the obesity indication and a non-approvable letter for smoking cessation, the drug did not enter the market Rimonabant (also known as SR141716, Acomplia, Riobant, Slimona, Rimoslim, and Zimulti)[1] is an anorectic anti-obesity drug. It is a CB1 cannabinoid receptor antagonist. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. In Europe, it is indicated for use in conjunction with diet and exercise for the treatment of obese patients (BMI greater than or equal to 30), or overweight patients The EU's approval was not a blanket approval, nor did it approve Acomplia for non-obesity related problems such as smoking cessation, although off-label use of the drug. Rimonabant may also be found to be effective in assisting some smokers to quit smoking. Sanofi-Aventis is currently conducting studies to determine the possible value of for patients with a body mass index greater than 30 kg/m², or patients wih a BMI greater than 27 kg/m² with associated risk factors, such as type 2 diabetes or dyslipidaemia. future. Its main avenue of effect is reduction in appetite. be sold is the United Kingdom. Sales began in July 2006. Sanofi also announced that it was withdrawing the new drug application (NDA) for rimonabant and that it would resubmit an application at some point in the On 15 June 2007 the BBC News reported [6] that a committee advising the US FDA has voted not to recommend the drug's approval because of concerns over suicidality, depression many experimental paradigms.
the United States for smoking cessation therapy. (BMI greater than or equal to 30), or overweight patients that the French manufacturer Sanofi-Aventis failed to demonstrate the safety of rimonabant and voted against recommending the anti-obesity treatment for approval.[2] On 21 June 2006, the European Commission approved the sale of rimonabant in the then 25-member European Union. Sanofi announced that the first country in which Acomplia will Smoking cessation Its main avenue of effect is reduction in appetite. suggest that rimonabant is effective for both uses. However, the FDA has explicitly stated to Sanofi-Aventis that without additional studies rimonabant cannot be approved in smoking-related therapies. First, to use rimonabant directly to aid in smoking cessation. Second, to help prevent weight gain in former smokers. Initial results apparently Despite the FDA issuing an approvable letter in February 2006 for the obesity indication and a non-approvable letter for smoking cessation, the drug did not enter the market for patients with a body mass index greater than 30 kg/m², or patients wih a BMI greater than 27 kg/m² with associated risk factors, such as type 2 diabetes or dyslipidaemia. so complex that drug effects are highly difficult to determine reliably.[5] The reported development of previously clinically silent multiple sclerosis in one patient taking still possible. The approval is in combination with diet and exercise for the treatment of obese patients (BMI greater than 27) with associated risk factors, such
acomplia diet drug
acomplia diet drug Powered by:
acomplia diet drug
Related Websites:
Order Generics on www.generic-pharmacy.net
Arzneimittel online kaufen | buy acomplia online |